<DOC>
	<DOCNO>NCT00182650</DOCNO>
	<brief_summary>RATIONALE : Cellular adoptive immunotherapy use person 's white blood cell treat laboratory stimulate immune system different way stop cancer cell grow . Rituximab fludarabine may also prevent body make immune response laboratory-treated white blood cell put back body . Interleukin-2 may help laboratory-treated white blood cell stay body longer . Giving cellular adoptive immunotherapy together rituximab , fludarabine , interleukin-2 may kill cancer cell . PURPOSE : This phase I trial study side effect cellular adoptive immunotherapy treat patient relapsed refractory follicular non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Cellular Adoptive Immunotherapy Treating Patients With Relapsed Refractory Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility cellular adoptive immunotherapy use autologous cytotoxic T lymphocytes genetically modify express CD19-specific chimeric immunoreceptor gene HyTK selection/suicide gene patient relapse refractory follicular non-Hodgkin 's lymphoma . Secondary - Determine vivo persistence adoptively transfer cytolytic T cell patient treat lymphodepleting therapy comprise rituximab fludarabine . - Assess development host immune response CD19-specific chimeric immunoreceptor gene and/or HyTK selection/suicide gene . - Determine safety low-dose interleukin-2 support vivo persistence adoptively transfer cytotoxic T cell . - Determine anti-tumor activity regimen patient . OUTLINE : This nonrandomized , open-label , pilot study . - Leukapheresis : Patients undergo leukapheresis collection peripheral blood mononuclear cell ( PBMCs ) . CD3-positive cytotoxic T lymphocytes ( CTLs ) isolate genetically modify express CD19-specific chimeric immunoreceptor HyTK fusion protein , expand vitro . - Lymphodepleting therapy : Patients receive rituximab fludarabine prior T-cell infusion . - Cellular adoptive immunotherapy interleukin-2 ( IL-2 ) : Patients receive total 5 infusion genetically modify autologous T cell . Patients may receive low-dose IL-2 subcutaneously infusion 3 , 4 , 5 . - Additional IL-2 therapy : After completion last T-cell infusion , patient evidence adoptively transfer T cell may receive additional IL-2 . After completion study treatment , patient follow periodically approximately 65 day annually least 15 year . PROJECTED ACCRUAL : At least 5 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm follicular nonHodgkin 's lymphoma ( NHL ) Highrisk disease , define follow : Relapsed within 6 month last treatment Failed achieve complete response last treatment Relapsed prior autologous hematopoietic stem cell transplantation ( HSCT ) No current transformation lymphoma ( e.g. , element intermediate highgrade lymphoma biopsy ) No active CNS disease lumbar puncture radiology scan NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 16 70 Performance status Karnofsky 50100 % Life expectancy More 16 week Hematopoietic Absolute neutrophil count &gt; 500/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) * ( unless due Gilbert 's disease ) ALT ≤ 2.5 time ULN* NOTE : *Unless due NHL Renal Creatinine ≤ 1.5 time ULN* OR Creatinine clearance ≥ 80 mL/min* NOTE : *Unless due NHL Immunologic HIV negative EpsteinBarr virus positive No history allergy intolerance ganciclovir Other Negative pregnancy test No history another malignancy except basal cell skin cancer carcinoma situ No uncontrolled severe illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy No prior allogeneic HSCT No immunotherapy approximately 65 day last Tcell infusion , unless approve Principal Investigator ( PI ) Chemotherapy No chemotherapy approximately 65 day last Tcell infusion , unless approve PI Patients may receive chemotherapy leukapheresis wait CD19specific T cell manufacture Endocrine therapy No systemic corticosteroid approximately 65 day last Tcell infusion , unless approve PI Radiotherapy Not specify Surgery Not specify Other No concurrent participation another investigational study No immunosuppression agent investigational agent approximately 65 day last Tcell infusion , unless approve PI</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>